Dr. Reynolds is a Vice Chancellors Senior Research Fellow in the School of Science at RMIT. He obtained his PhD in 2009 from the Chemistry & Biology departments of the University of Sheffield. Since then he has held positions at the University of Zurich, CSIRO, Swinburne University of Technology and La Trobe University.
Dr. Reynolds’ research is highly interdisciplinary and focuses on the design, discovery, characterisation and applications of self-assembled nanomaterials. These nanomaterials have applications in diverse fields including tissue engineering, regenerative medicine, sensing and understanding disease.
The goal of the self-assembled nanomaterials research group is to develop biomaterials and devices that have real and tangible benefits to communities in Australia and worldwide. For this to be possible, routes to translate our fundamental research to clinics, facilities and factories must be identified. Thus, Dr Reynolds collaborates with the MedTech industry, clinicians and government agencies to enable the translation of research outcomes into commercial devices, products and therapies. Dr Reynolds works closely with a number of commercial and clinical partners both in Australia and Oversees.
Dr. Reynolds has a wealth of experience teaching and co-ordinating undergraduate and postgraduate classes across the fields of biochemistry and chemistry.
Dr Reynolds research focusses on the design, discovery and characterisation of self-assembling biomolecules, these fundamental studies have applications in understanding the progression of diseases, developing biomaterials for regenerative medicine and bioprinting and the development of new point of use biosensors.
Current Projects in Dr Reynolds lab include
Understanding the role of protein aggregation in viral infections: Funded by an Australian Research Council (ARC) Discovery Project (DP250101215) Dr. Reynolds leads a team investigating how protein aggregation plays a role in a number of viral infections affecting both humans and livestock. Our research has shown that it is likely that aggregation of viral proteins from viruses including COVID-10 and influenza is contributing to some of the more severe symptoms of these infections. By understanding the molecular processes that drive viral protein aggregation in infected cells we can rationally design new therapies to treat existing and future viral threats.
Smart Materials for Bioprinting, Regenerative Medicine and Sensing: Self-assembling peptides that aggregate into nanofibrillar structures can be used to impart unique properties to soft biomaterials, for instance this allows us to develop hydrogels with tuneable mechanical properties that are also electrically responsive. By harnessing these unique properties we can design composite biomaterials that support and encourage human tissue regeneration. The developed materials will have applications in cartilage, muscle and neural tissue engineering. In addition through Dr Reynolds role as co-chief investigator in the ARC Research Hub for Molecular Biosensors at the Point of Use (MOBIUS) (IH240100013) he is working with the multinational bioprinting company CELLINK to develop new bioprintable materials with sensing capability that will allow the in situ monitoring of tissue growth and regeneration within these materials.
RMIT University acknowledges the people of the Woi wurrung and Boon wurrung language groups of the eastern Kulin Nation on whose unceded lands we conduct the business of the University. RMIT University respectfully acknowledges their Ancestors and Elders, past and present. RMIT also acknowledges the Traditional Custodians and their Ancestors of the lands and waters across Australia where we conduct our business - Artwork 'Sentient' by Hollie Johnson, Gunaikurnai and Monero Ngarigo.
More information